BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Treatment
2502 results:

  • 1. Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology.
    Marvaso G; Jereczek-Fossa BA; Zaffaroni M; Vincini MG; Corrao G; Andratschke N; Balagamwala EH; Bedke J; Blanck O; Capitanio U; Correa RJM; De Meerleer G; Franzese C; Gaeta A; Gandini S; Garibaldi C; Gerszten PC; Gillessen S; Grubb WR; Guckenberger M; Hannan R; Jhaveri PM; Josipovic M; Kerkmeijer LGW; Lehrer EJ; Lindskog M; Louie AV; Nguyen QN; Ost P; Palma DA; Procopio G; Rossi M; Staehler M; Tree AC; Tsang YM; Van As N; Zaorsky NG; Zilli T; Pasquier D; Siva S
    Lancet Oncol; 2024 May; 25(5):e193-e204. PubMed ID: 38697165
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.
    Uhlig J; Uhlig A; Deshpande H; Ströbel P; Trojan L; Lotz J; Hurwitz M; Hafez O; Humphrey P; Grünwald V; Kim HS
    Sci Rep; 2024 May; 14(1):10038. PubMed ID: 38693188
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
    Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
    JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genetic polymorphisms and clinical parameters associated with renal toxicity in Thai hematologic malignancy patients receiving high dose methotrexate.
    Pitakkitnukun P; Pongpitakmetha T; Suttichet TB; Sukkummee W; Chariyavilaskul P; Polprasert C
    Sci Rep; 2024 Apr; 14(1):9695. PubMed ID: 38678107
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
    Pei F; Tao Z; Lu Q; Fang T; Peng S
    World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Open versus minimally invasive nephroureterectomy in octogenarians: An analysis of surgical approach trends, outcomes, and survival analysis with propensity matching.
    Trecarten S; Bhandari M; Abdelaziz A; Noel O; Liss M; Dursun F; Svatek R; Mansour AM
    Urol Oncol; 2024 Jul; 42(7):220.e9-220.e19. PubMed ID: 38631967
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.
    Li H; Huntington S; Gross C; Wang SY
    PLoS One; 2024; 19(4):e0300789. PubMed ID: 38625861
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Robotic salvage partial nephrectomy following surgical and ablative therapies.
    Feng CL; Franco A; Ditonno F; Manfredi C; Chow AK; Autorino R
    Int Braz J Urol; 2024; 50(3):373-374. PubMed ID: 38598832
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinical safety and efficacy of microwave ablation for small renal masses.
    Foret A; Haaga CB; Jain S; Baumgartner CO; Escott M; Henderson BR; O'Brien ST; Delacroix SE; Gills JRR; Westerman ME
    Int Braz J Urol; 2024; 50(3):277-286. PubMed ID: 38598830
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Challenges and technical aspects in the management of muscle invasive bladder cancer as retrograde radical cystectomy with ileal conduit.
    Nusrat NB; Rehman AU; Zafar N; Muhammad S; Bajwa SI; Imtiaz S
    J Pak Med Assoc; 2024 Mar; 74(3):513-518. PubMed ID: 38591289
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology.
    Lee CM; Wang M; Rajkumar A; Calabrese C; Calabrese L
    Semin Arthritis Rheum; 2024 Jun; 66():152440. PubMed ID: 38579593
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
    Machiels JP; Tao Y; Licitra L; Burtness B; Tahara M; Rischin D; Alves G; Lima IPF; Hughes BGM; Pointreau Y; Aksoy S; Laban S; Greil R; Burian M; Hetnał M; Delord JP; Mesía R; Taberna M; Waldron JN; Simon C; Grégoire V; Harrington KJ; Swaby RF; Zhang Y; Gumuscu B; Bidadi B; Siu LL;
    Lancet Oncol; 2024 May; 25(5):572-587. PubMed ID: 38561010
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Long-term outcome of surgically treated and conservatively managed Rathke cleft cysts.
    Schmutzer-Sondergeld M; Weller J; Thorsteinsdottir J; Schichor C; Rachinger W; Thon N; Ueberschaer M
    Acta Neurochir (Wien); 2024 Apr; 166(1):159. PubMed ID: 38557782
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
    Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
    Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Association Between Acute kidney Injury and the Trendelenburg Position Angle During Robot-assisted Radical Prostatectomy.
    Masuda H; Amemiya Y; Yagisawa N; Arai T; Yanagisawa M
    Anticancer Res; 2024 Apr; 44(4):1767-1772. PubMed ID: 38538005
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Cancer-specific mortality in non-metastatic T1a renal cell carcinoma treated with radiotherapy versus partial nephrectomy.
    de Angelis M; Morra S; Scheipner L; Siech C; Jannello LMI; Baudo A; Goyal JA; Tian Z; Longo N; Ahyai S; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Montorsi F; Briganti A; Karakiewicz PI
    World J Urol; 2024 Mar; 42(1):193. PubMed ID: 38530480
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Stereotactic body radiotherapy for distant metastases to the head and neck.
    Mutsaers A; Abugharib A; Poon I; Loblaw J; Bayley A; Zhang L; Chin L; Galapin M; Erler D; Sahgal A; Higgins K; Enepekides D; Eskander A; Karam I
    Support Care Cancer; 2024 Mar; 32(4):230. PubMed ID: 38488881
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Percutaneous Image-Guided Cryoablation of Endophytic Renal Cell Carcinoma.
    Jensen CG; Dybdahl M; Valtersson J; Mussmann BR; Duus LA; Junker T; Pietersen PI; Lund L; Welch BT; Graumann O
    Cardiovasc Intervent Radiol; 2024 Apr; 47(4):453-461. PubMed ID: 38483602
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. 25 year trends in cancer incidence and mortality among adults aged 35-69 years in the UK, 1993-2018: retrospective secondary analysis.
    Shelton J; Zotow E; Smith L; Johnson SA; Thomson CS; Ahmad A; Murdock L; Nagarwalla D; Forman D
    BMJ; 2024 Mar; 384():e076962. PubMed ID: 38479774
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. ctDNA predicts clinical T1a to pathological T3a upstaging after partial nephrectomy.
    Park JS; Kim H; Jang WS; Kim J; Ham WS; Lee ST
    Cancer Sci; 2024 May; 115(5):1680-1687. PubMed ID: 38475661
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 126.